Business
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain ...
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ Patent Extends Jurisdiction and Protection Through 2042 ~","length":59,"tagName":"p"},{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce's MPAR® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's intellectual property estate for its unique overdose protection platform. The new issuance provides protection for the Company's MPAR® patent coverage through 2042 in this jurisdiction and expands the United States Patent No. 12,599,578 that issued on April 14, 2026.","length":950,"tagName":"p"},{"type":"text","content":"MPAR®, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), is engineered to reduce the impact of opioid exposure during an overdose. In clinical studies, PF614-MPAR provided effective pain relief when used as directed, while preventing excessive opioid release when multiple doses were taken. Ensysce has extended its MPAR® technology beyond opioids to other drug classes such as amphetamines and methadone to support the development of safer treatments for pain, ADHD, and opioid use disorder.","length":544,"tagName":"p"},{"type":"text","content":""MPAR® overdose protection, combined with our TAAP™ abuse‑deterrent platform, offers a dual‑layer safety approach that we believe is unmatched in the field," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. "This new patent marks another step in our mission to make essential, proven medicines safer and we are grateful for the support and funding from the National Institute on Drug Abuse¹. This funding has enabled us to demonstrate clinically that MPAR moderates opioid release when taken in excess and is currently supporting our second clinical trial evaluating this technology. We remain committed to advancing PF61...